Mydecine Innovations Group says it is well-funded to advance its IP portfolio and expand clinical trial calendar
The company has strengthened its balance sheet with approximately $30 million in capital raised CEO Josh Bartch said the firm has built its intellectual property portfolio to position Mydecine as 'a key player in the advancement of psychedelic-assisted psychotherapy' Mydecine Innovations Group (NEO:MYCO) (OTCMKTS:MYCOF) (FSE:0NFA) posted full year 2020 results that showed the company was well-funded to advance its intellectual property (IP) portfolio and expand its clinical trial calendar. As of December 31, 2020, the Denver, Colorado-based biopharma company focused on the res...